What did @tarasmodernlife1 actually say?
The core claim here is that injection site location directly affects how you feel on GLP-1 medications. Specifically, that the thigh delivers "stable energy, controlled appetite, and almost no symptoms," while the arm is the worst option, triggering nausea, fatigue, and what she calls "just not feeling right." She also flags the belly as nausea-prone and the flank as an underrated smooth option.
She's upfront that this is personal experience, saying "I know everyone reacts differently." That caveat matters. She's not citing studies. She's reporting her own n=1 experiment across multiple injection sites, ranking them by subjective symptom experience. That's worth separating from a clinical claim before we dig into what the research actually says.
Does the science back this up?
Partially, but not in the way she frames it. Pharmacokinetic studies do show that injection site affects drug absorption rate, but the evidence on symptom differences by site is much thinner than her confident ranking implies.
The clearest finding in the literature is that subcutaneous absorption varies by tissue blood flow and fat thickness. A 2021 review by Heise et al. in Diabetes Care confirmed that abdominal injections of insulin analogs (a related subcutaneous drug class) show faster absorption than thigh injections, partly due to higher regional blood flow. Whether this translates meaningfully to semaglutide or tirzepatide's once-weekly kinetics is not established. These are long-acting drugs with half-lives of roughly 7 days for semaglutide. Small absorption rate differences between sites are likely to wash out over that window.
On nausea specifically: the gastrointestinal side effects of GLP-1 agonists are driven by the drug's central and gut receptor activity, not by where you stuck the needle. There is no peer-reviewed evidence showing that abdominal injections cause more nausea than thigh injections for semaglutide or tirzepatide.
What did they get wrong (or right)?
She got the rotation advice right. Clinical guidelines from the American Diabetes Association and manufacturer prescribing information for both Ozempic and Wegovy recommend rotating injection sites to prevent lipohypertrophy, a localized thickening of fat tissue that can reduce drug absorption. That part of her message is sound.
Where she goes wrong is presenting her symptom pattern as something others should replicate. The thigh being her "number one" with "stable energy" and "controlled appetite" is not a transferable clinical finding. It's a post-hoc attribution. If her nausea improved over time and she happened to be injecting her thigh during that period, she would naturally associate the two. This is classic confirmation bias, and it's how a lot of wellness misinformation spreads on TikTok regardless of good intentions.
The arm criticism is also worth scrutinizing. She says the arm was "done more" and triggered the most side effects. Upper arm is an approved injection site per prescribing information. Difficulty self-injecting the arm without assistance is a real practical issue, but attributing systemic symptoms to that site is not supported by evidence.
What should you actually know?
Injection site does matter, but probably not in the way this video suggests. The documented reasons to care about site selection are lipohypertrophy prevention and consistent absorption, not symptom management by location.
Nausea and fatigue on GLP-1 medications are dose-dependent and tend to peak in the first few weeks or after dose escalations. A 2022 trial by Wilding et al. in The New England Journal of Medicine (the STEP 1 trial for semaglutide) documented that GI side effects were highest during titration and decreased over time for most participants. That timeline, not injection location, is the most reliable predictor of when symptoms ease.
If you are on a GLP-1 medication and managing side effects, the rotation schedule matters. Injecting repeatedly into the same spot builds up scar-like tissue that absorbs the drug inconsistently. That inconsistency could, in theory, affect both efficacy and tolerability. But picking one "winning" site and staying there is not the clinical recommendation.
- Approved sites for subcutaneous GLP-1 injection: abdomen, thigh, upper arm
- Rotate within and between sites each week
- Avoid injecting within 2 inches of the navel
- Symptom changes over time reflect dose titration, not site switching